Filing Details

Accession Number:
0000950170-25-021455
Form Type:
13G Filing
Publication Date:
2025-02-13 19:00:00
Filed By:
Anson Investments
Company:
Transcode Therapeutics Inc.
Filing Date:
2025-02-14
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Anson Funds Management LP 0 113,479 9.9%
Tony Moore 0 113,479 9.9%
Anson Advisors Inc. 0 113,479 9.9%
Amin Nathoo 0 113,479 9.9%
Moez Kassam 0 113,479 9.9%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G


 
Anson Funds Management LP
 
Signature:/s/ Tony Moore
Name/Title:Manager
Date:02/14/2025
 
Tony Moore
 
Signature:s/ Tony Moore
Name/Title:Tony Moore
Date:02/14/2025
 
Anson Advisors Inc.
 
Signature:/s/ Amin Nathoo
Name/Title:Director
Date:02/14/2025
 
Signature:/s/ Moez Kassam
Name/Title:Director
Date:02/14/2025
 
Amin Nathoo
 
Signature:/s/ Amin Nathoo
Name/Title:Amin Nathoo
Date:02/14/2025
 
Moez Kassam
 
Signature:/s/ Moez Kassam
Name/Title:Moez Kassam
Date:02/14/2025

Comments accompanying signature:  SCHEDULE 13G This Schedule 13G (the "Schedule 13G") is being filed on behalf of Anson Funds Management LP (d/b/a Anson Funds), a Texas limited partnership, Anson Management GP LLC, a Texas limited liability company, Mr. Tony Moore, the principal of Anson Funds Management LP and Anson Management GP LLC, Anson Advisors Inc., an Ontario, Canada corporation, Mr. Amin Nathoo, a director of Anson Advisors Inc., and Mr. Moez Kassam, a director of Anson Advisors Inc., relating to Common Stock, $0.0001 par value (the "Common Stock"), of Transcode Therapeutics, Inc., a Delaware corporation (the "Issuer"). This Schedule 13G relates to the Common Stock of the Issuer purchased by a private fund to which Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors (the "Fund"). Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors to the Fund and may direct the vote and disposition of the 113,479 shares of Common Stock held by the Fund. As the general partner of Anson Funds Management LP, Anson Management GP LLC may direct the vote and disposition of the 113,479 shares of Common Stock held by the Fund. As the principal of Anson Fund Management LP and Anson Management GP LLC, Mr. Moore may direct the vote and disposition of the 113,479 shares of Common Stock held by the Fund. As directors of Anson Advisors Inc., Mr. Nathoo and Mr. Kassam may each direct the vote and disposition of the 113,479 shares of Common Stock held by the Fund.
Exhibit Information

Exhibit 99.1 Joint Filing Agreement dated February 14, 2025, by and among Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam.